We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of Dendritic Cells in Hepatitis C Infection

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00723242
First Posted: July 28, 2008
Last Update Posted: July 28, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Schering-Plough
Information provided by:
University College, London
  Purpose
The role of the dendritic cells, the most potent antigen presenting cells, in the establishment of chronic hepatitis C is not established. The study aims to define whether the dendritic cells are affected by the hepatitis C virus and whether that bears an impact on the antiviral immune response they generate. The hypothesis is explored by investigating a group of patients prior to and after the initiation of standard treatment for hepatitis C with pegylated Interferon and Ribavirin.

Condition Intervention
Chronic Hepatitis C Infection Drug: Viraferon-peg and Rebetol

Study Type: Interventional
Study Design: Primary Purpose: Basic Science

Resource links provided by NLM:


Further study details as provided by University College, London:

Primary Outcome Measures:
  • Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin)

Study Start Date: April 2002
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • anti-HCV positive
  • HCV RNA positive

Exclusion Criteria:

  • contraindications for antiviral treatment
  • concurrent chronic viral infections
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00723242


Locations
United Kingdom
University College Hospital
London, United Kingdom, NW1 2BU
Sponsors and Collaborators
University College, London
Schering-Plough
  More Information

Responsible Party: Professor Nikolai V. Naoumov
ClinicalTrials.gov Identifier: NCT00723242     History of Changes
First Submitted: July 24, 2008
First Posted: July 28, 2008
Last Update Posted: July 28, 2008
Last Verified: July 2008

Additional relevant MeSH terms:
Infection
Hepatitis
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Ribavirin
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents